Indolent B-cell non-Hodgkin's lymphomas

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• Indolent B-cell non-Hodgkin's lymphomas (NHL) encompass a heterogeneous group of lymphoid malignancies.
• These lymphomas present with diverse clinical features and disease trajectories.
• Previous classifications, like the Working Formulation, grouped many distinct entities under the umbrella of indolent lymphomas.

Purpose of the Study:

• To review the spectrum of indolent B-cell non-Hodgkin's lymphomas.
• To discuss the heterogeneity in their presentation and natural history.
• To emphasize the need for further research and improved therapeutic strategies.

Main Methods:

• Literature review of indolent lymphoma classifications and entities.
• Synthesis of information on clinical presentation, natural history, and management variables.
• Discussion of current treatment limitations and future research directions.

Main Results:

• Identified key indolent lymphoma entities: small-lymphocytic lymphoma (SLL), lymphoplasmacytoid lymphoma, follicle center cell lymphomas, mantle cell lymphoma, and marginal zone lymphomas (including MALT lymphoma).
• Highlighted significant variability in presenting features and natural history among these subtypes.
• Underscored that current therapeutic approaches are insufficient for achieving widespread cures.

Conclusions:

• Indolent lymphomas represent a complex group of diseases requiring individualized management strategies.
• Patient-specific factors, disease characteristics, and treatment preferences significantly influence therapeutic decisions.
• Ongoing laboratory and clinical research is crucial for advancing the understanding and treatment of indolent lymphomas, aiming for improved patient outcomes.